Riskpilot← Back to searchSign inGet full accessBiopart Konsult AB
ABIn liquidationOrg 5591461362Engineering activities and related technical consultancy · NACE 7112Est. 20180 employees
Revenue 2022
SEK 0
EBITDA margin
—
-5% vs 2021
Equity ratio
81.9%
Financial strength
Net profit 2022
SEK -5K
-7% vs 2021
| Revenue | SEK 0 | — |
| EBITDA | SEK -5K | -5% |
| Net profit | SEK -5K | -7% |
| Total assets | SEK 55K | -9% |
| Equity | SEK 45K | -11% |
| Employees | 0 | — |
Legal name
Biopart Konsult AB
Org number
5591461362
Legal form
Aktiebolag
NACE code
7112 · Engineering activities and related technical consultancy
Founded
22 januari 2018
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av likvidatorn externa firmatecknarna
Company purpose
Föremålet för bolagets verksamhet är att bedriva konsultverksamhet inom anläggningsarbeten, byggledning och byggkontroll samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −8 | −1 | −14 | −5 | −5 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | — |
| EBIT | −8 | −1 | −14 | −5 | −5 |
| Net financials | — | — | — | — | −0 |
| Profit before tax | −8 | −1 | −15 | −5 | −5 |
| Tax | −0 | −0 | −0 | −0 | — |
| Net profit | −8 | −1 | −15 | −5 | −5 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Total assets | 51 | 48 | 36 | 61 | 55 |
| Equity | 42 | 41 | 26 | 51 | 45 |
| Long-term debt | 0 | 0 | 0 | 0 | — |
| Short-term debt | 9 | 7 | 10 | 10 | 10 |
| Total debt | 9 | 7 | 10 | 10 | 10 |
EBITDA margin
-525000.0%
This company
15.8%
Market median
-3322885% vs market
20182022
Equity ratio
81.9%
This company
38.2%
Market median
+114% vs market
20182022
Return on equity
-11.8%
This company
18.4%
Market median
-164% vs market
20182022
Net profit margin
-535300.0%
This company
8.1%
Market median
-6608742% vs market
20182022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20182022
Debt / equity
0.22×
This company
0.62×
Market median
+65% vs market
20182022
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
LB External Signatory | External Signatory | 2024 |
IM External Signatory | External Signatory | 2024 |
BJ Liquidator | Liquidator | 2024 |
UM External Signatory | External Signatory | 2024 |
| Former (1) | ||
ET Audit | Audit | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Board of Directors | 2020 – 2024 | |
| Deputy Board Member | 2020 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Biopart Konsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lena Birgitta Killgren Jonsson | External Signatory | 0 companies |
| Inger Margareta Dahle | External Signatory | 0 companies |
| Bengt Junior Niklas Nygårds | Liquidator | 0 companies |
| Ulrika Margareta Ahlholm | External Signatory | 0 companies |
| Erik Tomas Haglund | Audit | 0 companies |
| Hans Per Ulvebring | Board of Directors | 0 companies |
| Hans Bertil Ulvebring | Deputy Board Member | 0 companies |